In this episode, Jim Mazzo and John A. Hovanesian, MD, FACS, sit down with Bill Carpou, CEO of Octane, to discuss his transition to executive chairman of the organization.
· Tell us about your background. 2:24
· How has Octane changed under your leadership? What does the future hold? 4:01
· What does Octane do? 8:57
· What will be different, and what will remain the same? 12:07
· What are the differences between ophthalmology/optometry and other specialties? 15:20
· What trends are you seeing in eye care? 18:08
· What is causing the slowdown of cataract procedures? 20:21
We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John A. Hovanesian, MD, FACS, @DrHovanesian on Instagram and X and John Hovanesian on LinkedIn. To find out more about Octane, click here.
Disclosures: Carpou reports being CEO of Octane. Hovanesian reports consulting widely in the ophthalmic field and being a strategic medical advisor for Tenpoint Therapeutics. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Lab, Bain Capital, CVC Capital Partners and Zeiss; being executive chairman of Neurotech, Preceyes BV and TearLab; and sitting on the board of Centricity Vision, Crystilex, LensGen and Visus.
